DOPAMINE HYDROCHLORIDE (dopamine hydrochloride) by Pfizer is 3,4 dihydroxyphenylalanine (dopa). Approved for hemodynamic status in patients in shock. First approved in 1981.
Drug data last refreshed 11h ago · AI intelligence enriched 5d ago
Dopamine hydrochloride is a catecholamine injectable agent approved in 1981 for managing hemodynamic instability in patients in shock. It works as a precursor to norepinephrine and acts on dopamine, beta-1, and alpha-1 receptors in a dose-dependent manner to improve cardiac contractility and renal perfusion.
This product is in late-stage decline with loss of exclusivity approaching, indicating consolidation and reduced team investment by sponsor Pfizer.
3,4 dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal tract, and in a few peripheral sympathetic nerves. Dopamine elicits its pharmacological…
Dopamine HCl offers minimal career growth opportunity given LOE-approaching lifecycle and zero linked job postings. Positions on this product are primarily operational/maintenance roles managing market wind-down rather than strategic development.
Worked on DOPAMINE HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo